OncoMatch/Clinical Trials/NCT06751134
Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma
Is NCT06751134 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Chimeric Natural Killer Receptor Universal T-cells (CNK-UT) for neuroblastoma, recurrent, refractory.
Treatment: Chimeric Natural Killer Receptor Universal T-cells (CNK-UT) — This is a single arm, open-label, multi-center, pilot studies (Investigator Initiated Trial, IIT) to evaluate the safety, preliminary efficacy, pharmacokinetics of universal T-cells engineered with chimeric natural killer receptor (CNK-UT) to treat the patients with relapsed/refractory Neuroblastoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Neuroblastoma
Biomarker criteria
Required: CD276 expression (positive by ihc)
Prior therapy
Must have received: induction chemotherapy — first-line
standard treatment protocols, which include induction chemotherapy, surgery, and radiotherapy targeting the primary tumor and residual metastatic sites
Must have received: surgery — first-line
standard treatment protocols, which include induction chemotherapy, surgery, and radiotherapy targeting the primary tumor and residual metastatic sites
Must have received: radiation therapy — first-line
standard treatment protocols, which include induction chemotherapy, surgery, and radiotherapy targeting the primary tumor and residual metastatic sites
Cannot have received: gene therapy
Participants who have used any gene therapy products prior to cell infusion
Lab requirements
Blood counts
ANC≥1.5×10^9/L; ALC≥0.2×10^9/L; Platelet count ≥75×10^9/L; Haemoglobin≥90g/L
Kidney function
Serum creatinine≤2×ULN, or Creatinine clearance rate (CCR)≥60 mL/min (Cockroft-Gault formula)
Liver function
Total bilirubin≤3×ULN; AST or ALT≤5×ULN
Cardiac function
LVEF≥50%; Cardiac function Grade I-II
Adequate organ and bone marrow function, and the laboratory test value meets the following requirements within 7 days before enrollment, as follows: (1)Blood Routine Test: Absolute neutrophil count(ANC)≥1.5×10^9/L;Absolute lymphocyte count (ALC)≥0.2×10^9/L；Platelet count ≥75×10^9/L; Haemoglobin≥90g/L; (2)Heart: Left ventricular ejection fraction (LVEF)≥50%;Cardiac function Grade I-II; (3)Pulmonary function: indoor oxygen saturation≥92%. (4)Hepatic function：Total bilirubin≤3×ULN; Aspartate aminotransferase (AST) or alanine aminotransferase (ALT)≤5×ULN; (5)Renal function: Serum creatinine≤2×ULN, or Creatinine clearance rate (CCR)≥60 mL/min (Cockroft-Gault formula);
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify